CY1121060T1 - Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση - Google Patents

Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση

Info

Publication number
CY1121060T1
CY1121060T1 CY181101300T CY181101300T CY1121060T1 CY 1121060 T1 CY1121060 T1 CY 1121060T1 CY 181101300 T CY181101300 T CY 181101300T CY 181101300 T CY181101300 T CY 181101300T CY 1121060 T1 CY1121060 T1 CY 1121060T1
Authority
CY
Cyprus
Prior art keywords
protosal
leichmanasis
triazolo
pyrimidine
derivatives
Prior art date
Application number
CY181101300T
Other languages
English (en)
Inventor
Agnes Biggart
Fang Liang
Casey Jacob Nelson Mathison
Valentina Molteni
Advait Suresh Nagle
Frantisek Supek
Vince Yeh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52302387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121060(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1121060T1 publication Critical patent/CY1121060T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις του Τύπου Α: ή ένα φαρμακευτικώς αποδεκτό άλας, ταυτομερές, ή στερεοϊσομερές αυτών, όπου οι μεταβλητές είναι όπως ορίζονται στο παρόν. Η παρούσα εφεύρεση παρέχει περαιτέρω φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις και μεθόδους χρήσης τέτοιων ενώσεων για θεραπεία, πρόληψη, αναστολή, ανακούφιση, ή εξάλειψη της παθολογίας ή/και της συμπτωματολογίας μιας ασθένειας που προκαλείται από ένα παράσιτο, όπως η λεϊσμανίαση, η ανθρώπινη αφρικανική τρυπανοσωμίαση και η νόσος Chagas.
CY181101300T 2013-12-19 2018-12-05 Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση CY1121060T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361918089P 2013-12-19 2013-12-19
PCT/US2014/071077 WO2015095477A1 (en) 2013-12-19 2014-12-18 [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis

Publications (1)

Publication Number Publication Date
CY1121060T1 true CY1121060T1 (el) 2019-12-11

Family

ID=52302387

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101300T CY1121060T1 (el) 2013-12-19 2018-12-05 Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση

Country Status (41)

Country Link
US (6) US9303034B2 (el)
EP (1) EP3083627B1 (el)
JP (1) JP6392352B2 (el)
KR (1) KR102354082B1 (el)
CN (1) CN106029666B (el)
AP (1) AP2016009329A0 (el)
AR (1) AR098844A1 (el)
AU (1) AU2014364565B2 (el)
BR (1) BR112016014004B1 (el)
CA (1) CA2932870C (el)
CL (1) CL2016001421A1 (el)
CR (1) CR20160334A (el)
CU (1) CU24379B1 (el)
CY (1) CY1121060T1 (el)
DK (1) DK3083627T3 (el)
EA (1) EA030823B1 (el)
EC (1) ECSP16067921A (el)
ES (1) ES2701087T3 (el)
GT (1) GT201600131A (el)
HR (1) HRP20182021T1 (el)
HU (1) HUE040254T2 (el)
IL (1) IL246034B (el)
LT (1) LT3083627T (el)
MA (1) MA39186A1 (el)
MX (1) MX368072B (el)
MY (1) MY175865A (el)
NZ (1) NZ721650A (el)
PE (1) PE20160865A1 (el)
PH (1) PH12016501198A1 (el)
PL (1) PL3083627T3 (el)
PT (1) PT3083627T (el)
RS (1) RS58053B1 (el)
SG (1) SG11201604618TA (el)
SI (1) SI3083627T1 (el)
SV (1) SV2016005226A (el)
TN (1) TN2016000253A1 (el)
TW (1) TWI674263B (el)
UA (1) UA117046C2 (el)
UY (1) UY35903A (el)
WO (1) WO2015095477A1 (el)
ZA (1) ZA201604415B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303336A1 (en) 2015-05-29 2018-04-11 GlaxoSmithKline Intellectual Property Development Limited Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents
WO2017025416A1 (en) * 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2017127627A1 (en) 2016-01-21 2017-07-27 The University Of North Carolina At Chapel Hill Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
TW202028208A (zh) * 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]三唑并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
FR2652085A1 (fr) 1989-09-20 1991-03-22 Science Organisation Nouveau procede de synthese de derives d'oxazolopyridines.
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0643588A (ja) * 1992-07-27 1994-02-18 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3735741B2 (ja) * 1995-11-24 2006-01-18 株式会社大塚製薬工場 縮環ピリミジン誘導体
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
WO1998010779A1 (en) * 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
CA2402516A1 (en) 2000-03-20 2001-09-27 Roopa Rai Non-amidine containing protease inhibitors
AU2001259707A1 (en) 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
AU2002216649A1 (en) 2000-10-31 2002-05-15 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
US20020127605A1 (en) 2000-11-28 2002-09-12 Hamilton Gregory S. Bisubstituted carbocyclic cyclophilin binding compounds and their use
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
EA007339B1 (ru) 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
PT1452528E (pt) 2001-11-16 2008-10-14 Nippon Chemiphar Co Inibidores de xantina-oxidase
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
CN1860121A (zh) * 2003-07-30 2006-11-08 S.A.L.V.A.T.实验室有限公司 用于预防和治疗癌症的取代咪唑并嘧啶
EP1651198A2 (en) 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
WO2005030206A1 (en) 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
US7432278B2 (en) 2004-03-08 2008-10-07 The University Of North Carolina At Chapel Hill Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents
CN101087787A (zh) 2004-12-23 2007-12-12 霍夫曼-拉罗奇有限公司 苯甲酰胺衍生物，它们的制备及作为药剂的应用
CN101830899A (zh) 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
WO2007017143A1 (en) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
WO2007014707A1 (en) 2005-08-01 2007-02-08 F. Hoffmann-La Roche Ag Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
CA2617532A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
CA2656810C (en) 2006-07-11 2012-03-13 Daewoong Pharmaceutical Co., Ltd. Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008100376A2 (en) 2007-02-15 2008-08-21 Sirtris Pharmaceuticals, Inc. Truncation variants of sirt1 and methods of use thereof
CA2681813A1 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2682676A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
TW200932872A (en) 2007-10-17 2009-08-01 Cheil Ind Inc Novel compound for organic photoelectric device and organic photoelectric device including the same
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010027746A2 (en) 2008-08-25 2010-03-11 Irm Llc Hedgehog pathway modulators
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
JO3156B1 (ar) * 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
PT2483274E (pt) * 2009-09-29 2015-02-04 Univ Texas Agentes antimaláricos que são inibidores de di-hidro-orotato desidrogenase
WO2011094708A2 (en) * 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
US20130150351A1 (en) 2010-06-03 2013-06-13 Stanley T. Carmichael Methods and compositions for treating a subject for central nervous system (cns) injury
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2012130633A1 (en) 2011-03-25 2012-10-04 Boehringer Ingelheim International Gmbh Pyrazole compounds as crth2 antagonists
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
CA2855372C (en) 2011-11-11 2022-03-22 Nimbus Apollo, Inc. 2,4-dioxo-thieno[2,3-d]pyrimidinyl derivatives and pharmaceutical compositions thereof used as acc inhibitors
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
CA2866450C (en) * 2012-03-07 2020-02-18 Merck Patent Gmbh Triazolopyrazine derivatives
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TW201406736A (zh) 2012-06-28 2014-02-16 Fujifilm Corp 新穎的醯胺衍生物或其鹽
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
AU2013305475B2 (en) 2012-08-21 2017-10-12 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Also Published As

Publication number Publication date
JP2017501177A (ja) 2017-01-12
WO2015095477A1 (en) 2015-06-25
IL246034B (en) 2020-02-27
CA2932870C (en) 2021-11-09
US20150175613A1 (en) 2015-06-25
TW201609734A (zh) 2016-03-16
UA117046C2 (uk) 2018-06-11
EA201691271A1 (ru) 2016-12-30
PT3083627T (pt) 2018-11-30
KR20160093077A (ko) 2016-08-05
CN106029666A (zh) 2016-10-12
ECSP16067921A (es) 2017-10-31
MY175865A (en) 2020-07-14
PE20160865A1 (es) 2016-09-03
NZ721650A (en) 2018-12-21
SG11201604618TA (en) 2016-07-28
ES2701087T3 (es) 2019-02-20
CL2016001421A1 (es) 2016-12-30
EP3083627B1 (en) 2018-09-05
US20170333437A1 (en) 2017-11-23
EA030823B1 (ru) 2018-10-31
DK3083627T3 (da) 2019-01-02
AU2014364565A1 (en) 2016-07-14
PH12016501198A1 (en) 2016-08-15
US10596175B2 (en) 2020-03-24
EP3083627A1 (en) 2016-10-26
HRP20182021T1 (hr) 2019-01-25
US10085989B2 (en) 2018-10-02
MX368072B (es) 2019-09-18
IL246034A0 (en) 2016-08-02
US9303034B2 (en) 2016-04-05
SV2016005226A (es) 2019-04-23
US11123348B2 (en) 2021-09-21
CU20160090A7 (es) 2017-05-10
CU24379B1 (es) 2019-02-04
AR098844A1 (es) 2016-06-15
US20160303129A1 (en) 2016-10-20
US20190000852A1 (en) 2019-01-03
US20200179391A1 (en) 2020-06-11
TN2016000253A1 (en) 2017-10-06
BR112016014004A2 (el) 2017-08-08
HUE040254T2 (hu) 2019-02-28
ZA201604415B (en) 2017-09-27
KR102354082B1 (ko) 2022-01-24
TWI674263B (zh) 2019-10-11
AP2016009329A0 (en) 2016-07-31
CR20160334A (es) 2016-12-06
CN106029666B (zh) 2018-05-18
BR112016014004B1 (pt) 2022-11-01
MX2016008079A (es) 2016-09-16
CA2932870A1 (en) 2015-06-25
SI3083627T1 (sl) 2019-01-31
PL3083627T3 (pl) 2019-02-28
MA39186A1 (fr) 2017-11-30
RS58053B1 (sr) 2019-02-28
JP6392352B2 (ja) 2018-09-19
GT201600131A (es) 2018-12-18
UY35903A (es) 2015-07-31
LT3083627T (lt) 2018-12-27
AU2014364565B2 (en) 2017-06-15
US9700559B2 (en) 2017-07-11
US20210369716A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
CY1121060T1 (el) Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
ECSP18083519A (es) Inhibidores de bromodominios
DOP2015000308A (es) Inhibidores de bromodominios
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
CR20140413A (es) Inhibidores de serina/treonina cinasa
ECSP20018703A (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
EA201692300A1 (ru) Производные карбоксамида
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
CR20170546A (es) Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios
EA201791743A1 (ru) Производные имидазо[2,1-в]тиазола и 5,6-дигидроимидазо[2,1-в]тиазола, применяемые в качестве s100-ингибиторов
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний